NICE vs. Workiva: Which Technology Stock Is a Better Buy in 2026?

NICE reported FY 2025 revenue of nearly $2.9 billion, up about 7.7%, with net income of roughly $612.1 million, a 20.8% net margin, and $703.2 million of free cash flow. Workiva grew FY 2025 revenue to about $884.6 million, up nearly 19.7%, but still posted a net loss of approximately $26.2 million. The article argues Workiva offers the better 2026 buy despite NICE's cheaper valuation (7.8x forward P/E vs. 16.1x for Workiva), making this mainly a stock-selection and valuation comparison rather than a major market-moving event.

Analysis

NICE looks like the cleaner cash-generation story, but the market is already paying up for that quality via confidence in durable margins. The more interesting setup is that NICE’s low multiple may be signaling skepticism about how long AI can preserve pricing power in customer experience before the functionality gets commoditized by larger suites and generic copilots. That creates a classic “good business, capped multiple” profile: upside exists, but it likely needs either a re-acceleration in organic growth or a meaningful AI monetization surprise to rerate.

Workiva has the better asymmetry if you think compliance spend is becoming more strategic rather than cyclical. The key second-order effect is that regulatory reporting is moving from a back-office workflow to a board-level risk management function, which should lift contract sizes and reduce churn even if headline growth moderates. The counterpoint is concentration: if one regulatory wedge remains oversized, the stock can still de-rate quickly on any hint that expansion into sustainability is slowing or that Microsoft bundle pressure is intensifying.

The market is likely underestimating how differently these names respond to macro. NICE is more exposed to enterprise cost-cutting cycles; in a slowdown, automation demand helps, but seat expansion and upsell decisions can still get delayed. Workiva is less economically sensitive but more event-driven: it should trade on regulatory catalysts, large customer wins, and proof that sustainability/reporting is broadening beyond a niche add-on. Over the next 6-12 months, the better trade is not to chase the absolute winner, but to own the name where execution can still change the multiple.

Contrarian read: the consensus framing of “profitability vs growth” misses that Workiva’s valuation can expand faster than NICE’s if it proves it is becoming mission-critical infrastructure, while NICE may be stuck proving AI value in a crowded category. That makes NICE the safer balance sheet story and Workiva the higher-conviction rerating candidate if growth stays near current levels.

Key Decisions for Investors

• Long WK / short NICE as a 6-9 month relative-value pair if you expect multiple expansion to favor the higher-growth name; stop if WK growth decelerates below mid-teens or NICE re-accelerates guide.
• Buy WK on 10-15% post-earnings weakness over the next 1-2 quarters; target a 20-30% upside move if management reiterates raised outlook and sustainability attach rates improve.
• Use NICE as a defensive quality long only on a pullback toward the low end of its historical forward P/E range; risk/reward is attractive only if you believe AI pricing power is still underappreciated.
• Consider a call spread on WK for the next two earnings cycles to express rerating potential while limiting downside from valuation compression.
• Avoid initiating a fresh outright short in NICE; instead, if bearish, express it via a pair trade against WK or a basket of software with clearer re-acceleration, since the balance sheet reduces single-name blowup risk.